Rita Barcia

Rita Barcia

Company: SIRPant Immunotherapeutics

Job title: Vice President, Process Development & Operations


A Novel Approach to Cancer-Agnostic Treatment of Tumors With Non-Genetically Modified Macrophages 2:00 pm

SIRpant uses a non-genetic approach to reprogramming macrophages that removes SIRPɑ and simultaneously reprograms them to promote an anti-cancer response whilst reducing manufacturing time  Our macrophages act by directly attacking cancerous cells, stimulating cancer neoantigen-specific cytotoxic T cells and antibodies, reducing immunosuppressive elements, and perpetuating a pro-inflammatory TME that favors cancer elimination  Overcoming manufacturing challenges…Read more

day: Day One Track A PM

© Copyright 2023 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.